VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.15%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$474M
AUM Growth
+$427M
(+909%)
Cap. Flow
+$429M
Cap. Flow
% of AUM
90.37%
Top 10 Holdings %
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20
Top Buys
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$6.67M |
| 2 |
Barings BDC
BBDC
|
$6.25M |
| 3 |
Oxford Square Capital
OXSQ
|
$5.46M |
| 4 |
ECC
Eagle Point Credit Co
ECC
|
$5.43M |
| 5 |
FS KKR Capital
FSK
|
$5.08M |
Top Sells
Sector Composition
| 1 | Financials | 23.58% |
| 2 | Real Estate | 14.99% |
| 3 | Energy | 13.55% |
| 4 | Healthcare | 12.23% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
151
DELISTED
Clovis Oncology, Inc.
CLVS
| $930K | 0.2% |
+62,509
| New | +$930K |
|
152
Lexicon Pharmaceuticals
LXRX
$389M
| $901K | 0.19% |
+143,272
| New | +$901K |
|
153
Ultragenyx Pharmaceutical
RARE
$3.04B
| $899K | 0.19% |
14,162
-2,223
| -14% | -$141K |
|
|
ALXN
154
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $899K | 0.19% |
+6,864
| New | +$899K |
|
|
RDUS
155
DELISTED
Radius Health, Inc.
RDUS
| $896K | 0.19% |
+36,795
| New | +$896K |
|
156
Acadia Pharmaceuticals
ACAD
$4.26B
| $892K | 0.19% |
+33,367
| New | +$892K |
|
157
Amicus Therapeutics
FOLD
$2.49B
| $890K | 0.19% |
71,320
-2,333
| -3% | -$29.1K |
|
158
Incyte
INCY
$16.7B
| $885K | 0.19% |
10,417
-1,096
| -10% | -$93.1K |
|
159
Halozyme
HALO
$8.63B
| $884K | 0.19% |
51,461
+626
| +1% | +$10.8K |
|
160
Exelixis
EXEL
$10.1B
| $878K | 0.19% |
41,091
+4,650
| +13% | +$99.4K |
|
|
STML
161
DELISTED
Stemline Therapeutics, Inc.
STML
| $875K | 0.18% |
57,127
+30,273
| +113% | +$464K |
|
162
Vertex Pharmaceuticals
VRTX
$102B
| $872K | 0.18% |
4,756
+329
| +7% | +$60.3K |
|
163
Nektar Therapeutics
NKTR
$708M
| $870K | 0.18% |
+1,631
| New | +$870K |
|
164
Gilead Sciences
GILD
$142B
| $864K | 0.18% |
+12,794
| New | +$864K |
|
165
Ligand Pharmaceuticals
LGND
$3.26B
| $860K | 0.18% |
12,080
+3,259
| +37% | +$232K |
|
166
BioMarin Pharmaceuticals
BMRN
$11B
| $858K | 0.18% |
10,013
+1,728
| +21% | +$148K |
|
167
Ironwood Pharmaceuticals
IRWD
$185M
| $854K | 0.18% |
78,060
-4,100
| -5% | -$44.9K |
|
|
PTLA
168
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $853K | 0.18% |
+31,436
| New | +$853K |
|
|
SAGE
169
DELISTED
Sage Therapeutics
SAGE
| $850K | 0.18% |
4,645
+2,000
| +76% | +$366K |
|
170
Amgen
AMGN
$153B
| $847K | 0.18% |
+4,597
| New | +$847K |
|
171
Travere Therapeutics
TVTX
$1.93B
| $847K | 0.18% |
+42,161
| New | +$847K |
|
|
MNTA
172
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $841K | 0.18% |
67,570
-1,745
| -3% | -$21.7K |
|
173
Agios Pharmaceuticals
AGIO
$2.12B
| $840K | 0.18% |
16,847
+2,307
| +16% | +$115K |
|
174
Alnylam Pharmaceuticals
ALNY
$59.1B
| $839K | 0.18% |
11,559
+1,297
| +13% | +$94.1K |
|
175
Ionis Pharmaceuticals
IONS
$9.66B
| $838K | 0.18% |
+13,037
| New | +$838K |
|